Related Experiment Video
Updated: Feb 4, 2026
![Assessment of Gastric Emptying in Non-obese Diabetic Mice Using a [13C]-octanoic Acid Breath Test](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F50301.jpg&w=3840&q=50)
Assessment of Gastric Emptying in Non-obese Diabetic Mice Using a [13C]-octanoic Acid Breath Test
Published on: March 23, 2013
Diabetic gastroparesis: current challenges and future prospects.
Danny J Avalos1, Irene Sarosiek1, Priyadarshini Loganathan2
1Division of Gastroenterology, Center for Neurogastroenterology and GI Motility, Texas Tech University Health Sciences Center, El Paso, TX, USA, richard.mccallum@ttuhsc.edu.
Diabetic gastroparesis (DMGP) management faces challenges due to limited effective treatments. This review highlights unmet needs and advances in drug development, endoscopic, and surgical interventions for improved patient outcomes.
Area of Science:
- Gastroenterology
- Endocrinology
- Pharmacology
Background:
- Diabetic gastroparesis (DMGP) is a debilitating complication of diabetes, characterized by delayed gastric emptying.
- Symptoms like nausea, vomiting, and abdominal pain significantly impair quality of life and increase healthcare costs.
- Current treatments, including metoclopramide, have limitations due to safety concerns and efficacy issues.
Purpose of the Study:
- To review the challenges in managing diabetic gastroparesis.
- To provide an update on novel therapeutic strategies for DMGP.
- To discuss advancements in drug development, endoscopic procedures, and surgical interventions.
Main Methods:
- Literature review of current research on diabetic gastroparesis management.
- Analysis of emerging pharmacological agents targeting gastric motility.
- Evaluation of surgical and endoscopic interventions for improving gastric emptying.
Main Results:
- Metoclopramide, the primary prokinetic, faces restrictions due to tardive dyskinesia risks.
- Several new prokinetic drugs with novel mechanisms are in development, showing promising early results.
- Endoscopic (gastric per-oral endoscopic pyloromyotomy) and surgical (gastric electrical stimulation with pyloroplasty) interventions offer improved gastric emptying and symptom relief.
Conclusions:
- There is a significant unmet need for safe and effective prokinetic agents for DMGP.
- Advances in drug development, endoscopic techniques, and surgical options are expanding therapeutic possibilities.
- A multimodal approach combining pharmacological, endoscopic, and surgical strategies may optimize DMGP management.
More Related Videos
16:26Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
Published on: August 20, 2007
04:09Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcers
Published on: March 3, 2023
Related Concept Videos
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Electrical Current
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Psychoneuroimmunology: Diabetes and Cancer
Current Density
Eddy Currents
Other major applications of eddy currents appear in metal detectors and the braking systems of trains and roller...